How to appeal a Blue Cross NC specialty biologics denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Blue Cross NC-specific note: BCBS licensee for North Carolina (~4.3M members). Prime Therapeutics PBM. NC DOI oversight. Blue Premier is the high-profile value-based care program. Recently divested some Medicaid business; Healthy Blue (joint venture with Elevance) handles NC Medicaid.

What Blue Cross NC's policy requires for specialty biologics

Cited policy: Anthem/Elevance Clinical UM Guideline clinical guideline - Adalimumab and Biosimilars

Moderate-severe disease + conventional therapy failure + TB/Hep B/C screening. Most BCBS plans now require biosimilar adalimumab first (2024-2026 adoption wave).

How Blue Cross NC denies specialty biologics — and how to counter it

Where Blue Cross NC pushes back: 1) Drug non-formulary; 2) Step therapy: failure of two preferred TNFi biosimilars required; 3) Lab work older than 12 months; 4) Missing rheumatologist/dermatologist/gastroenterologist attestation.

Counter-arguments that hold up: Identify the specific BCBS subsidiary and cite its named policy by number — generic appeals are weaker. For BCBS FEP: governed by FEHB; appeals to OPM after internal exhaustion (5 CFR 890.105). State external review under NAIC Model Act timelines. For self-funded ERISA BCBS plans: demand full claim file under 29 CFR 2560.503-1(h)(2)(iii).

What Blue Cross NC typically denies for specialty biologics

Across Blue Cross NC's commercial and Medicare books, denials cluster around a small number of patterns. For specialty biologics, expect:

• Step therapy via Prime Therapeutics
• Blue Premier value-based arrangement disputes
• Out-of-network reductions
• Specialty drug PA

Treatments most often denied in this category

These are the specialty biologics treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Humira
• Enbrel
• Remicade
• Stelara
• Skyrizi
• Cosentyx

How to submit the appeal to Blue Cross NC

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Blue Cross NC cited in the denial.
3. File the appeal through Blue Cross NC's portal (members: https://www.bluecrossnc.com ; providers: https://www.bluecrossnc.com/providers). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In NC, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Blue Cross NC's prior-authorization criteria by drug: Blue Cross NC PA criteria on ApprovalHelp.